![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NEUROCHEM COMPLETES RECRUITMENT FOR PHASE III ALZHEMED
NEUROCHEM COMPLETES RECRUITMENT FOR PHASE III ALZHEMED
Neurochem has completed recruitment of the 950 patients with mild-to-moderate Alzheimer's disease (AD) for its North American Phase III clinical trial for Alzhemed, the company's investigational product candidate for the treatment of AD.
The trial is being conducted in 51 U.S. and 17 Canadian clinical centers. Neurochem has completed the selection of sites for a similarly sized Phase III clinical trial in Europe and expects to begin patient recruitment for the study this fall.
The multi-center, randomized, double-blind, placebo-controlled and parallel designed North American Phase III clinical trial is investigating the safety and efficacy of Alzhemed for the treatment of AD in mild-to- moderate patients. The patients have been randomized to receive either placebo or one of two different dose levels of Alzhemed (100 mg or 150 mg, twice daily) for a period of 18 months.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct